Insider Buying: Veru Inc (NASDAQ:VERU) Director Acquires $19,500.00 in Stock
Veru Inc (NASDAQ:VERU) Director Jesus Socorro acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $1.95 per share, with a total value of $19,500.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of VERU opened at $1.92 on Thursday. Veru Inc has a 12-month low of $1.18 and a 12-month high of $2.49. The stock has a fifty day moving average price of $2.20. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.08. The company has a market cap of $132.03 million, a PE ratio of -4.92 and a beta of 0.37.
Veru (NASDAQ:VERU) last issued its earnings results on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Veru had a negative return on equity of 50.68% and a negative net margin of 59.68%. The company had revenue of $9.73 million for the quarter, compared to analysts’ expectations of $8.11 million. Analysts anticipate that Veru Inc will post -0.18 earnings per share for the current fiscal year.
Several brokerages have recently commented on VERU. ValuEngine raised shares of Veru from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. Cantor Fitzgerald began coverage on shares of Veru in a research report on Monday, July 1st. They set an “overweight” rating and a $6.00 price objective for the company. Zacks Investment Research downgraded shares of Veru from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Brookline Capital Management initiated coverage on Veru in a report on Monday, July 29th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.50 target price on shares of Veru in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $5.71.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Recommended Story: What causes a recession?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.